日本非感染性葡萄膜炎患者的真实世界治疗模式:一项使用大规模索赔数据库的描述性研究(J-CAT研究)。

IF 2.3 Q1 OPHTHALMOLOGY
Sentaro Kusuhara, Koh-Hei Sonoda, Toshikatsu Kaburaki, Tachie Fujita, Saki Katayama, Misako Makishima, Takao Nakamura, Mariko Nio, Takashi Omoto, Yukari Matsuo-Tezuka, Tomoki Yoshizaki, Kensuke Sasaki, Kairi Ri, Keiko Sato, Hiroshi Goto
{"title":"日本非感染性葡萄膜炎患者的真实世界治疗模式:一项使用大规模索赔数据库的描述性研究(J-CAT研究)。","authors":"Sentaro Kusuhara, Koh-Hei Sonoda, Toshikatsu Kaburaki, Tachie Fujita, Saki Katayama, Misako Makishima, Takao Nakamura, Mariko Nio, Takashi Omoto, Yukari Matsuo-Tezuka, Tomoki Yoshizaki, Kensuke Sasaki, Kairi Ri, Keiko Sato, Hiroshi Goto","doi":"10.1186/s12348-025-00514-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Non-infectious uveitis (NIU) can arise from various inflammatory disorders and can cause vision loss. Patients with mild NIU are typically treated with corticosteroid eye drops to reduce intraocular inflammation; however, other local/systemic treatments (corticosteroids, immunosuppressants, biologics) may be required for moderate-to-severe NIU, which may cause ocular complications. Here, we investigated real-world treatment patterns for NIU in Japan.</p><p><strong>Methods: </strong>Patients were selected from a large, Japanese insurance claims database using International Classification of Diseases, Tenth Revision codes; diagnosis of NIU was confirmed via ophthalmological examination (October 2016-October 2023). Sankey diagrams were used to describe treatment transitions. Post-treatment ocular complications, potentially related surgeries, and fundus findings associated with uveitis were determined.</p><p><strong>Results: </strong>The majority of patients (68.7%; 37,869/55,091) were treated with corticosteroid eye drops only for mild NIU; 19.0% (10,449/55,091) were given other treatments for moderate-to-severe NIU, mostly oral corticosteroids (7,473/10,449) and posterior sub-Tenon's corticosteroid injections (1,636/10,449). In patients treated with corticosteroids orally or via sub-Tenon's injections, common transitions were to corticosteroid eye drops or censor (end of treatment/dataset or insurance withdrawal). A higher incidence of treatment-related ocular complications and potentially related surgeries (including glaucoma) was observed during the first year of NIU treatment compared with subsequent years (for moderate-to-severe NIU, estimated incidence of prescription of glaucoma drugs was 106 per 1,000 person-years [at 1 year], 73 per 1,000 person-years [at 2 years], and 52 per 1,000 person-years [at 5 years]).</p><p><strong>Conclusion: </strong>Our comprehensive analysis of a large claims database included all prescribed medications and medical procedures (including local injections) for NIU treatment in Japan up to October 2023. Although corticosteroids are a mainstay of NIU treatment in Japan, we found that a number of treatments for moderate-to-severe NIU, other than corticosteroid eye drops, are frequently used in combination with or when switching from corticosteroid eye drops. These findings are of importance when assessing the treatment landscape and may help identify unmet clinical needs in patients with NIU.</p>","PeriodicalId":16600,"journal":{"name":"Journal of Ophthalmic Inflammation and Infection","volume":"15 1","pages":"56"},"PeriodicalIF":2.3000,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12283504/pdf/","citationCount":"0","resultStr":"{\"title\":\"Real-world treatment patterns for patients with non-infectious uveitis in Japan: a descriptive study using a large-scale claims database (J-CAT study).\",\"authors\":\"Sentaro Kusuhara, Koh-Hei Sonoda, Toshikatsu Kaburaki, Tachie Fujita, Saki Katayama, Misako Makishima, Takao Nakamura, Mariko Nio, Takashi Omoto, Yukari Matsuo-Tezuka, Tomoki Yoshizaki, Kensuke Sasaki, Kairi Ri, Keiko Sato, Hiroshi Goto\",\"doi\":\"10.1186/s12348-025-00514-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Non-infectious uveitis (NIU) can arise from various inflammatory disorders and can cause vision loss. Patients with mild NIU are typically treated with corticosteroid eye drops to reduce intraocular inflammation; however, other local/systemic treatments (corticosteroids, immunosuppressants, biologics) may be required for moderate-to-severe NIU, which may cause ocular complications. Here, we investigated real-world treatment patterns for NIU in Japan.</p><p><strong>Methods: </strong>Patients were selected from a large, Japanese insurance claims database using International Classification of Diseases, Tenth Revision codes; diagnosis of NIU was confirmed via ophthalmological examination (October 2016-October 2023). Sankey diagrams were used to describe treatment transitions. Post-treatment ocular complications, potentially related surgeries, and fundus findings associated with uveitis were determined.</p><p><strong>Results: </strong>The majority of patients (68.7%; 37,869/55,091) were treated with corticosteroid eye drops only for mild NIU; 19.0% (10,449/55,091) were given other treatments for moderate-to-severe NIU, mostly oral corticosteroids (7,473/10,449) and posterior sub-Tenon's corticosteroid injections (1,636/10,449). In patients treated with corticosteroids orally or via sub-Tenon's injections, common transitions were to corticosteroid eye drops or censor (end of treatment/dataset or insurance withdrawal). A higher incidence of treatment-related ocular complications and potentially related surgeries (including glaucoma) was observed during the first year of NIU treatment compared with subsequent years (for moderate-to-severe NIU, estimated incidence of prescription of glaucoma drugs was 106 per 1,000 person-years [at 1 year], 73 per 1,000 person-years [at 2 years], and 52 per 1,000 person-years [at 5 years]).</p><p><strong>Conclusion: </strong>Our comprehensive analysis of a large claims database included all prescribed medications and medical procedures (including local injections) for NIU treatment in Japan up to October 2023. Although corticosteroids are a mainstay of NIU treatment in Japan, we found that a number of treatments for moderate-to-severe NIU, other than corticosteroid eye drops, are frequently used in combination with or when switching from corticosteroid eye drops. These findings are of importance when assessing the treatment landscape and may help identify unmet clinical needs in patients with NIU.</p>\",\"PeriodicalId\":16600,\"journal\":{\"name\":\"Journal of Ophthalmic Inflammation and Infection\",\"volume\":\"15 1\",\"pages\":\"56\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2025-07-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12283504/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Ophthalmic Inflammation and Infection\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/s12348-025-00514-5\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Ophthalmic Inflammation and Infection","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s12348-025-00514-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:非感染性葡萄膜炎(NIU)可由各种炎症性疾病引起,可导致视力丧失。轻度NIU患者通常使用皮质类固醇滴眼液治疗,以减少眼内炎症;然而,可能需要其他局部/全身治疗(皮质类固醇,免疫抑制剂,生物制剂),这可能导致中度至重度的眼部并发症。在这里,我们调查了日本的现实治疗模式。方法:采用国际疾病分类第十次修订代码,从大型日本保险理赔数据库中选择患者;2016年10月- 2023年10月眼科检查确诊为牛牛。Sankey图用于描述治疗过渡。治疗后的眼部并发症,潜在的相关手术,以及与葡萄膜炎相关的眼底检查结果被确定。结果:绝大多数患者(68.7%;37,869/55,091),仅用于轻度NIU的皮质类固醇滴眼液;19.0%(10,449/55,091)的患者接受了其他治疗,主要是口服皮质类固醇(7,473/10,449)和后路tenon亚皮质类固醇注射(1,636/10,449)。在口服或注射皮质类固醇的患者中,常见的过渡是使用皮质类固醇滴眼液或检查(治疗/数据集结束或保险退出)。与随后几年相比,在NIU治疗的第一年观察到与治疗相关的眼部并发症和潜在相关手术(包括青光眼)的发生率更高(对于中重度NIU,青光眼药物处方的估计发生率为106 / 1000人年[1年],73 / 1000人年[2年],52 / 1000人年[5年])。结论:我们对一个大型索赔数据库进行了综合分析,其中包括截至2023年10月在日本治疗NIU的所有处方药和医疗程序(包括局部注射)。虽然皮质类固醇在日本是治疗NIU的主要药物,但我们发现,除了皮质类固醇滴眼液外,还有一些治疗中度至重度NIU的药物经常与皮质类固醇滴眼液联合使用或在改用皮质类固醇滴眼液时使用。这些发现在评估治疗前景时具有重要意义,并可能有助于确定NIU患者未满足的临床需求。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Real-world treatment patterns for patients with non-infectious uveitis in Japan: a descriptive study using a large-scale claims database (J-CAT study).

Purpose: Non-infectious uveitis (NIU) can arise from various inflammatory disorders and can cause vision loss. Patients with mild NIU are typically treated with corticosteroid eye drops to reduce intraocular inflammation; however, other local/systemic treatments (corticosteroids, immunosuppressants, biologics) may be required for moderate-to-severe NIU, which may cause ocular complications. Here, we investigated real-world treatment patterns for NIU in Japan.

Methods: Patients were selected from a large, Japanese insurance claims database using International Classification of Diseases, Tenth Revision codes; diagnosis of NIU was confirmed via ophthalmological examination (October 2016-October 2023). Sankey diagrams were used to describe treatment transitions. Post-treatment ocular complications, potentially related surgeries, and fundus findings associated with uveitis were determined.

Results: The majority of patients (68.7%; 37,869/55,091) were treated with corticosteroid eye drops only for mild NIU; 19.0% (10,449/55,091) were given other treatments for moderate-to-severe NIU, mostly oral corticosteroids (7,473/10,449) and posterior sub-Tenon's corticosteroid injections (1,636/10,449). In patients treated with corticosteroids orally or via sub-Tenon's injections, common transitions were to corticosteroid eye drops or censor (end of treatment/dataset or insurance withdrawal). A higher incidence of treatment-related ocular complications and potentially related surgeries (including glaucoma) was observed during the first year of NIU treatment compared with subsequent years (for moderate-to-severe NIU, estimated incidence of prescription of glaucoma drugs was 106 per 1,000 person-years [at 1 year], 73 per 1,000 person-years [at 2 years], and 52 per 1,000 person-years [at 5 years]).

Conclusion: Our comprehensive analysis of a large claims database included all prescribed medications and medical procedures (including local injections) for NIU treatment in Japan up to October 2023. Although corticosteroids are a mainstay of NIU treatment in Japan, we found that a number of treatments for moderate-to-severe NIU, other than corticosteroid eye drops, are frequently used in combination with or when switching from corticosteroid eye drops. These findings are of importance when assessing the treatment landscape and may help identify unmet clinical needs in patients with NIU.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.80
自引率
3.40%
发文量
39
审稿时长
13 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信